Please provide your email address to receive an email when new articles are posted on . Women with advanced ovarian cancer derived significant quality-adjusted PFS benefit from niraparib compared with ...

Ovarian cancer remains one of the most lethal gynecologic malignancies worldwide, with a high risk of recurrence even after successful initial treatment. Over the past decade, poly(ADP-ribose) ...

The MyChoice CDx was approved based on its performance determining HRD status and stratifying patients in the phase 3 PRIMA trial. The FDA has approved the MyChoice CDx test as a companion diagnostic ...

Five branded products, four tumor types, and a regulatory arc that walked back late-line ovarian approvals even as AKEEGA just reached hormone-sensitive prostate cancer.